RecruitingRecruiting
Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
NCT04050345 · Royal Marsden NHS Foundation Trust
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
TRACC Part B: Despite potentially curative surgery +/- adjuvant chemotherapy, a proportional of patients with early stage CRC will experience disease relapse. Current tools for surveillance, e.g., blood sampling for tumour markers (CEA) are neither sensitive nor specific. We hypothesise that detection of mutations in circulating free DNA (cfDNA) in plasma can predict relapse in patients with early stage CRC.
Circulating cell free tumour DNA (ctDNA) maintains the same mutations that are present in tumour. In colorectal cancer CRC, primary tumours and\& metastases exhibit high genomic concordance. Therefore the TRACC study TRACC Part B is investigating whether serial blood samples taken from in patients with stage II and III fully resected early stage CRC colorectal cancer that have undergone potentially curative surgery, blood samples to can be used to detect and\& quantify ctDNA may in order to identify minimal residual disease MRD and predict relapse earlier than existing methods. CtDNA may ultimately help identify a subset of patients that are or are unlikely to benefit from adjuvant chemotherapy and could therefore safely spare some patients from receiving unnecessary chemotherapy \& its associated side-effects.
TRACC Part C: We hypothesis that ctDNA guided adjuvant chemotherapy administration will enable biomarker driven selection of patients who would and would not benefit from adjuvant chemotherapy and thereby reduce the proportion of patient receiving unnecessary adjuvant chemotherapy, reducing the potential side effects associated with it, but without compromising disease free survival (DFS). : This part of the study will use tThe blood test ctDNA result from a post-operative blood sample willto guide adjuvant chemotherapy treatment decisions. The study aims to demonstrate that athe de -escalation strategy of ctDNA guided adjuvant chemotherapy is non-inferior to standard of care treatment as measured by 3 year DFS in patients with high risk stage II and stage III CRC, in those who have no evidence of MRD (ctDNA negative). after surgery for patients with colorectal cancer who are following the standard of care pathway. Patients are randomised at the post- operative time point to: Arm A (standard of care adjuvant chemotherapy), or Arm B (ctDNA guided adjuvant chemotherapy) arm. For the ct DNA guided arm, patients who are ctDNA negative at this time point will have their chemotherapy de-escalated.
Eligibility criteria
TRACC Part B Inclusion Criteria:
* New diagnosis of histologically confirmed CRC scheduled to undergo surgery with curative intent, with no radiological evidence of metastatic disease.
* Patients with high grade dysplasia whose imaging is suggestive of colorectal carcinoma (CRC) will be included but will be excluded post-surgery if carcinoma diagnosis is not confirmed
* Age≥18
* Ability to give informed consent
* Able to adhere to follow up schedule
TRACC Part B Exclusion Criteria:
* Scheduled to have neoadjuvant chemotherapy, (neoadjuvant chemoradiotherapy for patients with rectal cancer is permitted)
* Current or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix or other non-invasive malignancy
TRACC Part C
Inclusion Criteria:
1. Subject ≥ 18 years of age
2. Subjects with histologically proven high risk stage II or stage III colon or rectal cancer treated with curative intent with surgery alone (any T, N1 or N2) with no evidence of metastatic disease. High risk stage II is defined as having one or more of the following: T4 disease, obstruction and/or perforation of the primary tumour during the pre-operative period, inadequate nodal harvest as indicated by \<12 nodes examined, poorly differentiated grade on histology, perineural invasion, peritoneal involvement or extramural venous/lymphatic invasion. Subjects must be due to receive adjuvant chemotherapy after surgery or Subjects with histologically proven locally advanced stage III rectal cancer treated with neoadjuvant chemoradiotherapy (any T, N1 or N2, M0) with no evidence of metastatic disease are eligible. Subjects must be due to receive adjuvant chemotherapy after surgery
3. Fully surgically resected tumour with clear resection margins (i.e., \>1 mm).
4. Adequate organ function
* Absolute neutrophil function ≥1.0 x 109/ L
* Platelet Count ≥ 75 x 109 / L
* Haemoglobin ≥80g/L (blood transfusion before randomisation is allowed)
* Adequate renal function (GFR ≥ 50ml/min if single agent capecitabine or CAPOX being administered) as calculated by Cockcroft and Gault equation
* Aspartate aminotransferase/ Alanine aminotransferase levels ≤ 2.5 upper limit of normal
5. Absence of major post-operative complications or other clinical conditions that, in the opinion of the investigator, would contraindicate adjuvant chemotherapy
6. Patients should be assessed by Oncology team for suitability and assessment for adjuvant chemotherapy, be able to have post-operative ctDNA sample collected and be randomised by week 8 ± 2 weeks after surgery.
7. ECOG performance status 0- 2
8. Able to give informed consent
TRACC Part C Exclusion criteria
1\. History of concurrent and previous malignancy within the last 5 years, with the exception of non- melanomatous skin cancer and carcinoma in situ 2. Any major post-operative complications or other clinical conditions that in the opinion of the investigator would contra-indicate adjuvant chemotherapy 3. Any subject not due to receive adjuvant chemotherapy will not be eligible for Part C of the study 4. Hypersensitivity or contraindication to the drug(s) associated with the planned choice of systemic chemotherapy (CAPOX or single agent capecitabine) as stated in the SmPC for each of the drugs 5. Subjects due to receive 5-Flurouracil (5-FU) based adjuvant chemotherapy (either single agent 5-FU or in combination with oxaliplatin) will not be eligible for Part C of the study
\-
Study design
Enrollment target: 1000 participants
Age groups: adult, older_adult
Timeline
Starts: 2016-12-05
Estimated completion: 2031-07-31
Last updated: 2024-06-14
Primary outcomes
- • TRACC Part B (Translational sub study) (6 years)
- • TRACC Part C (Randomised ctDNA guided adjuvant chemotherapy versus SoC study): (4 years)
Sponsor
Royal Marsden NHS Foundation Trust · other
Contacts & investigators
ContactHsiang-Chi Chen, MSc · contact · TRACCStudy@rmh.nhs.uk · 02086426011
ContactSusie Slater, Dr · contact
InvestigatorDavid Cunningham · study_chair, Royal Marsden NHS Foundation Trust
All locations (71)
Milton Keynes General HospitalRecruiting
Milton Keynes, Buckinghamshire, United Kingdom
Croydon University HospitalRecruiting
Thornton Heath, Croydon, United Kingdom
Dorset County Hospital NHS Foundation TrustRecruiting
Dorchester, Dorset, United Kingdom
Poole HospitalRecruiting
Poole, Dorset, United Kingdom
Broomfield HospitalRecruiting
Chelmsford, Essex, United Kingdom
Christie NHS Foundation TrustRecruiting
Manchester, Greater Manchester, United Kingdom
Queen Alexandra HospitalRecruiting
Portsmouth, Hampshire, United Kingdom
University Hospital of South Manchester & Manchester Royal InfirmaryRecruiting
Wythenshawe, Manchester, United Kingdom
Musgrove Park HospitalRecruiting
Taunton, Somerset, United Kingdom
Weston General HospitalRecruiting
Weston-super-Mare, Somerset, United Kingdom
Epsom and St Helier's Hospitals NHS TrustActive Not Recruiting
Carshalton, Surrey, United Kingdom
The Royal Marsden NHS Foundation TrustRecruiting
Sutton, Surrey, United Kingdom
Guy's & St Thomas HospitalRecruiting
London, UK, United Kingdom
Bradford Royal InfirmaryRecruiting
Bradford, West Yorkshire, United Kingdom
Salisbury District HospitalRecruiting
Salisbury, Whiltshire, United Kingdom
Aberdeen Royal InfirmaryRecruiting
Aberdeen, United Kingdom
Bronglais HospitalRecruiting
Aberystwyth, United Kingdom
Stoke Mandeville HospitalRecruiting
Aylesbury, United Kingdom
Basildon and Thurrock University HospitalsRecruiting
Basildon, United Kingdom
Basingstoke and North Hampshire HospitalsRecruiting
Basingstoke, United Kingdom
Bedford HospitalRecruiting
Bedford, United Kingdom
Royal Blackburn Teaching HospitalRecruiting
Blackburn, United Kingdom
Pilgrim HospitalRecruiting
Boston, United Kingdom
Royal Bournemouth HospitalRecruiting
Bournemouth, United Kingdom
University Hospitals Bristol NHS Foundation TrustRecruiting
Bristol, United Kingdom
Burnley General Teaching HospitalRecruiting
Burnley, United Kingdom
West Suffolk HospitalRecruiting
Bury, United Kingdom
Addenbrookes HospitalRecruiting
Cambridge, United Kingdom
Kent and Canterbury HospitalRecruiting
Canterbury, United Kingdom
North Cumbria University HospitalsRecruiting
Carlisle, United Kingdom
Glangwili HospitalRecruiting
Carmarthen, United Kingdom
Castle Hill HospitalRecruiting
Cottingham, United Kingdom
University Hospitals Coventry & WarwickshireRecruiting
Coventry, United Kingdom
Leighton HospitalRecruiting
Crewe, United Kingdom
University Hospital CrosshouseRecruiting
Crosshouse, United Kingdom
Medway NHS Foundation TrustActive Not Recruiting
Gillingham, United Kingdom
Beatson West of Scotland Cancer CentreRecruiting
Glasgow, United Kingdom
The Princess Alexandra Hospital NHS TrustRecruiting
Harlow, United Kingdom
Withybush General HospitalRecruiting
Haverfordwest, United Kingdom
Wycombe HospitalRecruiting
High Wycombe, United Kingdom
Calderdale and Huddersfield NHS Foundation TrustRecruiting
Huddersfield, United Kingdom
Airedale General HospitalRecruiting
Keighley, United Kingdom
Kettering General HospitalRecruiting
Kettering, United Kingdom
Kingston Hospital Foundation TrustRecruiting
Kingston upon Thames, United Kingdom
Forth Valley Royal HospitalRecruiting
Larbert, United Kingdom
St James's University HospitalRecruiting
Leeds, United Kingdom
Lincoln County HospitalRecruiting
Lincoln, United Kingdom
Prince Philip HospitalRecruiting
Llanelli, United Kingdom
Barts Health NHS TrustRecruiting
London, United Kingdom
North Middlesex University Hospital NHS TrustRecruiting
London, United Kingdom
Royal Free HospitalRecruiting
London, United Kingdom
St George's NHS Foundation TrustActive Not Recruiting
London, United Kingdom
The Royal Marsden NHS Foundation Trust - LondonRecruiting
London, United Kingdom
Chelsea and WestminsterActive Not Recruiting
London, United Kingdom
Maidstone & Tunbridge Wells NHS TrustRecruiting
Maidstone, United Kingdom
Chase Farm HospitalRecruiting
Middlesex, United Kingdom
Northampton General Hospital NHS TrustRecruiting
Northampton, United Kingdom
Nottingham University HospitalActive Not Recruiting
Nottingham, United Kingdom
George Eliot HospitalRecruiting
Nuneaton, United Kingdom
Royal Preston Hospital, Lancashire Teaching HospitalsRecruiting
Preston, United Kingdom
Barking Havering and Redbridge NHS Foundation Trust (Queen's HospitalRecruiting
Romford, United Kingdom
Weston Park HospitalRecruiting
Sheffield, United Kingdom
Royal Shrewsbury HospitalRecruiting
Shrewsbury, United Kingdom
South Tyneside District HospitalRecruiting
South Shields, United Kingdom
University Hospital SouthamptonRecruiting
Southampton, United Kingdom
Stockport NHS Foundation TrustRecruiting
Stockport, United Kingdom
Sunderland Royal HospitalRecruiting
Sunderland, United Kingdom
King's Mill HospitalRecruiting
Sutton in Ashfield, United Kingdom
Singleton HospitalRecruiting
Swansea, United Kingdom
Wrightington, Wigan and Leigh NHS Foundation TrustRecruiting
Wigan, United Kingdom
Royal Hampshire County HospitalRecruiting
Winchester, United Kingdom